Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial

Sanne M. van der Made, Jogchum Plat, Ronald P. Mensink

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: In vitro and animal studies have shown positive effects of resveratrol on lipid and lipoprotein metabolism, but human studies specifically designed to examine these effects are lacking. OBJECTIVE: The primary outcome parameter of this study in overweight and slightly obese subjects was the effect of resveratrol on apoA-I concentrations. Secondary outcome parameters were effects on other markers of lipid and lipoprotein metabolism, glucose metabolism, and markers for inflammation and endothelial function. DESIGN: This randomized, placebo-controlled crossover study was conducted in 45 overweight and slightly obese men (n = 25) and women (n = 20) with a mean age of 61 +/- 7 years. Subjects received in random order resveratrol (150 mg per day) or placebo capsules for 4 weeks, separated by a 4-week wash-out period. Fasting blood samples were collected at baseline and at the end of each intervention period. RESULTS: Compliance was excellent as indicated by capsule count and changes in resveratrol and dihydroresveratrol concentrations. No difference between resveratrol and placebo was found in any of the fasting serum or plasma metabolic risk markers (mean +/- SD for differences between day 28 values of resveratrol vs. placebo: apoA-I; 0.00 +/- 0.12 g/L (P = 0.791), apoB100; -0.01 +/- 0.11 g/L (P = 0.545), HDL cholesterol; 0.00 +/- 0.09 mmol/L (P = 0.721), LDL cholesterol -0.03 +/- 0.57 mmol/L (P = 0.718), triacylglycerol; 0.10 +/- 0.54 mmol/L (P = 0.687), glucose; -0.08 +/- 0.28 mmol/L (P = 0.064), insulin; -0.3 +/- 2.5 mU/L (P = 0.516)). Also, no effects on plasma markers for inflammation and endothelial function were observed. No adverse events related to resveratrol intake were observed. CONCLUSION: 150 mg of daily resveratrol intake for 4 weeks does not change metabolic risk markers related to cardiovascular health in overweight and slightly obese men and women. Effects on glucose metabolism warrant further study. TRIAL REGISTRATION: ClinicalTrials.gov NCT01364961.
Original languageEnglish
Article numbere0118393
Number of pages13
JournalPLOS ONE
Volume10
Issue number3
DOIs
Publication statusPublished - 19 Mar 2015

Keywords

  • CORONARY-HEART-DISEASE
  • APOLIPOPROTEIN-A-I
  • DENSITY-LIPOPROTEIN CHOLESTEROL
  • HDL CHOLESTEROL
  • CLINICAL-TRIAL
  • SUPPLEMENTATION
  • ATHEROSCLEROSIS
  • ALPHA
  • CONSUMPTION
  • PREVENTION

Cite this